BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Evidence Sheets

Evidence Sheet: Procter & Gamble (PG)

Moe Alsumidaie by Moe Alsumidaie
September 21, 2026
in Evidence Sheets
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

This is the standing evidence sheet for Procter & Gamble (PG): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.

The price tag: what buyers pay per dollar of profit

Today the market pays about $21.2 for each $1 of Procter & Gamble’s annual profit (a price-to-earnings ratio of 21.2). Across its own past decade the typical price tag was 23.9, which puts today at roughly the 9th percentile of the company’s own history.

The tape: what the stock itself has done

  • Last price: $146.39 (end-of-day market data as of the edition date · methodology) · 12% below its 52-week high
  • Past 6 months: +1.1% · past 12 months: -8.7%
  • Day-to-day temperament: normal (annualized volatility 20%)

The filed record: straight from the annual reports

Fiscal year Revenue Growth Operating margin EPS
FY2022 $80.2B +5.3% 22.2% $5.81
FY2023 $82.0B +2.3% 22.1% $5.9
FY2024 $84.0B +2.5% 22.1% $6.02
FY2025 $84.3B +0.3% 24.3% $6.51
FY2026 $87.0B +3.3% 22.7% $6.62

The road ahead: filed results vs published expectations

FY2024A FY2025A FY2026A FY2027E FY2028E
Net sales ($B) 84.0 84.3 87.0 89.5 to 93.0 92.0 to 97.0
Net sales growth (%) +0.4 +0.4 +3.2 2.9 to 6.9 2.8 to 4.3
Operating margin (%) 22.0 24.3 22.6 22.0 to 23.5 22.0 to 24.0
Diluted EPS ($) 6.02 6.51 6.62 6.50 to 7.10 6.60 to 7.65
R&D ($B) 2.0 2.1 2.1 2.1 to 2.2 2.1 to 2.3

Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.

The four gauges: from the latest edition

Can it keep growing?: 55/100 (higher is better)Can it keep growing?55higher is betterCompetition pressure: 68/100 (higher is worse)Competition pressure68higher is worseLegal & political risk: 42/100 (higher is worse)Legal & political risk42higher is worseCost & margin risk: 62/100 (higher is worse)Cost & margin risk62higher is worse
Hover any bar for the reading. Scored 0–100 in the latest edition; green is favorable on every bar.

Read the full report on Procter & Gamble in the BullScope Terminal → It opens with this company loaded.

Edition date: 2026-08-17. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Procter & Gamble’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Evidence Sheet: Honeywell International (HON)

by Moe Alsumidaie
October 21, 2026
0

The standing BullScope yardsticks for Honeywell International, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: Chevron (CVX)

by Moe Alsumidaie
October 20, 2026
0

The standing BullScope yardsticks for Chevron, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: General Electric (GE)

by Moe Alsumidaie
October 22, 2026
0

The standing BullScope yardsticks for General Electric, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: American Express (AXP)

by Moe Alsumidaie
October 16, 2026
0

The standing BullScope yardsticks for American Express, computed from official filings and refreshed with each new edition.

Read moreDetails

Evidence Sheet: Morgan Stanley (MS)

by Moe Alsumidaie
October 16, 2026
0

The standing BullScope yardsticks for Morgan Stanley, computed from official filings and refreshed with each new edition.

Read moreDetails
Next Post

Viatris: The Business Is Turning, the Price Tag Already Knows It

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Bank of America Is Priced for a Bank It Has Never Quite Been

August 14, 2026

Corcept Therapeutics: One Drug Fading, One Just Born, and a Stock Priced for Neither

September 29, 2026

Biogen’s stock has climbed 65% in a year. Its earnings have not.

September 28, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.